HB Wealth Management LLC Grows Position in Edwards Lifesciences Corporation (NYSE:EW)

HB Wealth Management LLC increased its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 34.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 21,562 shares of the medical research company’s stock after purchasing an additional 5,577 shares during the period. HB Wealth Management LLC’s holdings in Edwards Lifesciences were worth $1,563,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Equitable Trust Co. boosted its stake in shares of Edwards Lifesciences by 3.1% during the 1st quarter. Equitable Trust Co. now owns 75,273 shares of the medical research company’s stock worth $5,456,000 after purchasing an additional 2,231 shares during the period. Caliber Wealth Management LLC KS purchased a new position in shares of Edwards Lifesciences during the 1st quarter worth about $1,696,000. Avantax Advisory Services Inc. boosted its stake in shares of Edwards Lifesciences by 10.7% during the 1st quarter. Avantax Advisory Services Inc. now owns 10,707 shares of the medical research company’s stock worth $776,000 after purchasing an additional 1,032 shares during the period. One Wealth Advisors LLC boosted its stake in shares of Edwards Lifesciences by 54.2% during the 1st quarter. One Wealth Advisors LLC now owns 18,304 shares of the medical research company’s stock worth $1,327,000 after purchasing an additional 6,431 shares during the period. Finally, AE Wealth Management LLC boosted its position in Edwards Lifesciences by 18.8% in the 1st quarter. AE Wealth Management LLC now owns 90,502 shares of the medical research company’s stock valued at $6,560,000 after buying an additional 14,334 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on EW shares. Evercore ISI boosted their price objective on shares of Edwards Lifesciences from $77.00 to $80.00 and gave the company an “in-line” rating in a research report on Friday. Barclays boosted their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday. Argus raised shares of Edwards Lifesciences to a “strong-buy” rating in a research report on Thursday, July 10th. Mizuho boosted their price objective on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the company an “outperform” rating in a research report on Friday. Finally, Morgan Stanley boosted their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 15th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $85.00.

Edwards Lifesciences Stock Down 1.9%

NYSE:EW opened at $78.46 on Tuesday. The firm has a market capitalization of $46.02 billion, a P/E ratio of 11.29, a PEG ratio of 4.00 and a beta of 1.11. Edwards Lifesciences Corporation has a 1-year low of $59.41 and a 1-year high of $83.00. The company’s fifty day moving average price is $76.58 and its 200-day moving average price is $73.59. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.45 and a quick ratio of 3.66.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.25%. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.70 earnings per share. As a group, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 2,570 shares of the stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $77.40, for a total value of $198,918.00. Following the sale, the vice president owned 50,356 shares in the company, valued at $3,897,554.40. This represents a 4.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 34,962 shares of company stock valued at $2,641,387. 0.34% of the stock is owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.